231 related articles for article (PubMed ID: 10023511)
1. Effect of somatostatin infusion on the somatotrope responsiveness to growth hormone-releasing hormone in patients with anorexia nervosa.
Gianotti L; Rolla M; Arvat E; Belliti D; Valetto MR; Ferdeghini M; Ghigo E; Müller EE
Biol Psychiatry; 1999 Feb; 45(3):334-9. PubMed ID: 10023511
[TBL] [Abstract][Full Text] [Related]
2. Effects of beta-adrenergic agonists and antagonists on the growth hormone response to growth hormone-releasing hormone in anorexia nervosa.
Gianotti L; Arvat E; Valetto MR; Ramunni J; Di Vito L; Maccagno B; Camanni F; Ghigo E
Biol Psychiatry; 1998 Feb; 43(3):181-7. PubMed ID: 9494699
[TBL] [Abstract][Full Text] [Related]
3. Effects of free fatty acids and acipimox, a lipolysis inhibitor, on the somatotroph responsiveness to GHRH in anorexia nervosa.
Gianotti L; Fassino S; Daga GA; Lanfranco F; De Bacco C; Ramunni J; Arvat E; MacCario M; Ghigo E
Clin Endocrinol (Oxf); 2000 Jun; 52(6):713-20. PubMed ID: 10848875
[TBL] [Abstract][Full Text] [Related]
4. Somatostatin infusion withdrawal: studies in the acute and recovery phase of anorexia nervosa, and in obesity.
Pincelli AI; Rigamonti AE; Scacchi M; Cella SG; Cappa M; Cavagnini F; Müller EE
Eur J Endocrinol; 2003 Feb; 148(2):237-43. PubMed ID: 12590644
[TBL] [Abstract][Full Text] [Related]
5. Effects of recombinant human insulin-like growth factor I administration on the growth hormone (gh) response to GH-releasing hormone in obesity.
Maccario M; Tassone F; Gianotti L; Lanfranco F; Grottoli S; Arvat E; Muller EE; Ghigo E
J Clin Endocrinol Metab; 2001 Jan; 86(1):167-71. PubMed ID: 11231996
[TBL] [Abstract][Full Text] [Related]
6. Growth hormone responses to growth hormone-releasing hormone and hexarelin in fed and fasted dogs: effect of somatostatin infusion or pretreatment with pirenzepine.
Rigamonti AE; Marazzi N; Cella SG; Cattaneo L; Müller EE
J Endocrinol; 1998 Feb; 156(2):341-8. PubMed ID: 9518881
[TBL] [Abstract][Full Text] [Related]
7. Effect of withdrawal of somatostatin plus GH-releasing hormone as a stimulus of GH secretion in obesity.
Alvarez P; Isidro L; Leal-Cerro A; Casanueva FF; Dieguez C; Cordido F
Clin Endocrinol (Oxf); 2002 Apr; 56(4):487-92. PubMed ID: 11966741
[TBL] [Abstract][Full Text] [Related]
8. Arginine counteracts the inhibitory effect of recombinant human insulin-like growth factor I on the somatotroph responsiveness to growth hormone-releasing hormone in humans.
Gianotti L; Maccario M; Lanfranco F; Ramunni J; Di Vito L; Grottoli S; Muller EE; Ghigo E; Arvat E
J Clin Endocrinol Metab; 2000 Oct; 85(10):3604-8. PubMed ID: 11061509
[TBL] [Abstract][Full Text] [Related]
9. Arginine but not pyridostigmine, a cholinesterase inhibitor, enhances the GHRH-induced GH rise in patients with anorexia nervosa.
Ghigo E; Arvat E; Gianotti L; Nicolosi M; Valetto MR; Avagnina S; Bellitti D; Rolla M; Müller EE; Camanni F
Biol Psychiatry; 1994 Nov; 36(10):689-95. PubMed ID: 7880938
[TBL] [Abstract][Full Text] [Related]
10. The endocrine response to acute ghrelin administration is blunted in patients with anorexia nervosa, a ghrelin hypersecretory state.
Broglio F; Gianotti L; Destefanis S; Fassino S; Abbate Daga G; Mondelli V; Lanfranco F; Gottero C; Gauna C; Hofland L; Van der Lely AJ; Ghigo E
Clin Endocrinol (Oxf); 2004 May; 60(5):592-9. PubMed ID: 15104562
[TBL] [Abstract][Full Text] [Related]
11. Effect of withdrawal of somatostatin plus growth hormone (GH)-releasing hormone as a stimulus of GH secretion in Cushing's syndrome.
Leal-Cerro A; Soto A; Martínez MA; Alvarez P; Isidro L; Casanueva FF; Dieguez C; Cordido F
Clin Endocrinol (Oxf); 2002 Dec; 57(6):745-9. PubMed ID: 12460324
[TBL] [Abstract][Full Text] [Related]
12. Interaction of the growth hormone releasing peptide hexarelin with somatostatin.
Massoud AF; Hindmarsh PC; Brook CG
Clin Endocrinol (Oxf); 1997 Nov; 47(5):537-47. PubMed ID: 9425393
[TBL] [Abstract][Full Text] [Related]
13. Growth hormone (GH) rebound rise following somatostatin infusion withdrawal: studies in dogs with the use of GH-releasing hormone and a GH-releasing peptide.
Rigamonti AE; Cavallera G; Bonomo S; Deghenghi R; Locatelli V; Cella SG; Müller EE
Eur J Endocrinol; 2001 Nov; 145(5):635-44. PubMed ID: 11720883
[TBL] [Abstract][Full Text] [Related]
14. GH and cortisol rebound rise during and following a somatostatin infusion: studies in dogs with the use of a GH-releasing peptide.
Rigamonti AE; Bonomo SM; Cella SG; Müller EE
J Endocrinol; 2002 Sep; 174(3):387-94. PubMed ID: 12208658
[TBL] [Abstract][Full Text] [Related]
15. Effects of recombinant human insulin-like growth factor I administration on growth hormone (GH) secretion, both spontaneous and stimulated by GH-releasing hormone or hexarelin, a peptidyl GH secretagogue, in humans.
Ghigo E; Gianotti L; Arvat E; Ramunni J; Valetto MR; Broglio F; Rolla M; Cavagnini F; Müller EE
J Clin Endocrinol Metab; 1999 Jan; 84(1):285-90. PubMed ID: 9920097
[TBL] [Abstract][Full Text] [Related]
16. Reduction of the somatotrope responsiveness to GHRH and Hexarelin but not to arginine plus GHRH in hyperprolactinemic patients.
Grottoli S; Razzore P; Arvat E; Oleandri SE; Rossetto R; Ciccarelli E; Camanni F; Ghigo E
J Endocrinol Invest; 1997 Nov; 20(10):597-602. PubMed ID: 9438917
[TBL] [Abstract][Full Text] [Related]
17. Aspects of the neuroendocrine control of somatotropic function in calorically restricted dogs and patients with eating disorders: studies with cholinergic drugs.
Müller EE; Rolla M
Psychiatry Res; 1996 Apr; 62(1):51-63. PubMed ID: 8739115
[TBL] [Abstract][Full Text] [Related]
18. Effect of cholinergic muscarinic receptor blockade on human growth hormone (GH)-releasing hormone-(1-44)-induced GH secretion in anorexia nervosa.
Tamai H; Komaki G; Matsubayashi S; Kobayashi N; Mori K; Nakagawa T; Truong MP; Walter RM; Kumagai LF
J Clin Endocrinol Metab; 1990 Mar; 70(3):738-41. PubMed ID: 2106528
[TBL] [Abstract][Full Text] [Related]
19. The activity of GH/IGF-I axis in anorexia nervosa and in obesity: a comparison with normal subjects and patients with hypopituitarism or critical illness.
Gianotti L; Broglio F; Ramunni J; Lanfranco F; Gauna C; Benso A; Zanello M; Arvat E; Ghigo E
Eat Weight Disord; 1998 Jun; 3(2):64-70. PubMed ID: 10728152
[TBL] [Abstract][Full Text] [Related]
20. Further evidence of cholinergic impairment of the neuroendocrine control of the GH secretion in Down's syndrome.
Beccaria L; Marziani E; Manzoni P; Arvat E; Valetto MR; Gianotti L; Ghigo E; Chiumello G
Dement Geriatr Cogn Disord; 1998; 9(2):78-81. PubMed ID: 9524798
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
